ArticleScientific reports2021
The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 89 citations in OpenAlex.
- EB1010, a putative Christensenellaceae-derived microbial peptide, exhibits anti-inflammatory activity and therapeutic potential in ulcerative colitis.Gut microbes · 2026Article
- Article
- Christensenella minuta DSM 22607 and Food Restriction Manage Age-Related Disorders In Vivo.Probiotics and antimicrobial proteins · 2026Article
- Article
- Amelioration of colitis through restored gut ecology using Christensenella intestinihominis AF73-05CM02 as a probiotic in mice.Communications biology · 2026Article
- Cedrol ameliorates ulcerative colitisWorld journal of gastroenterology · 2026Article
- Pedal effect: aerobic and facultative anaerobic Enterobacter hormaechei maintain the homeostasis of the house fly gut microbiota under different oxygen conditions.Parasites & vectors · 2025Article
- Spatial proximity dictates bacterial competition and expansion in microbial communities.Nature communications · 2025Article
- Membrane vesicles produced by next-generation probiotics from the gut as innovative tools for human health.Gut microbes · 2025Review
- Evaluating the anti-inflammatory and antioxidant efficacy of complementary and alternative medicines (CAM) used for management of inflammatory bowel disease: a comprehensive review.Redox report : communications in free radical research · 2025Review
- Potential and Challenges ofFoods (Basel, Switzerland) · 2025Review
- Article
- Effects of Rumen-Protected Methionine and Lysine on the Fecal Microbiota of Leizhou Goats.Microorganisms · 2025Article
- Dynamics of tissue and fecal microbiota in active Crohn's disease and their ability to predict disease state.World journal of gastrointestinal pathophysiology · 2025Article
- Microbial proteases as emerging anti-inflammatory therapeutics: a comprehensive review.Archives of microbiology · 2025Review
- Targeted Intervention Strategies for Maternal-Offspring Transmission of Christensenellaceae in Pigs via a Deep Learning Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions.Briefings in bioinformatics · 2025Review
- Chemopreventive Effects of Bioactive Peptides Derived from Black Soldier Fly Larvae Protein Hydrolysates in a Rat Model of Early-Stage Colorectal Carcinogenesis.International journal of molecular sciences · 2025Article
- Optimising Nutrition for Sustainable Pig Production: Strategies to Quantify and Mitigate Environmental Impact.Animals : an open access journal from MDPI · 2025Review
- Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity.Cell reports. Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Christensenellaceae is a family of subdominant commensal bacteria found in humans. It is thought to play an important role in gut health by maintaining microbial symbiosis. Indeed, these bacteria occur at significantly lower levels or are absent in individuals suffering from inflammatory bowel diseases (IBDs). Here, we explored if type species Christensenella minuta (strain: DSM 22607) could have the potential to help treat IBDs. We assessed key properties displayed by the bacterium using a combination of in vitro and in vivo assays. We found that while C. minuta is a strict anaerobe, it is also oxygen tolerant. Additionally, we observed that the species produces high levels of acetate and moderate levels of butyrate. We performed deep phenotyping using Biolog microarrays. Using human intestinal cell lines, we discovered that C. minuta demonstrated strong anti-inflammatory activity, resulting in reduced levels of proinflammatory IL-8 cytokines via the inhibition of the NF-κB signaling pathway. Furthermore, C. minuta protected intestinal epithelial integrity in vitro. Finally, in two distinct animal models of acute colitis, C. minuta prevented intestinal damage, reduced colonic inflammation, and promoted mucosal healing. Together, these results indicate that C. minuta has potent immunomodulatory properties, underscoring its potential use in innovative microbiome-based IBD biotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.